Dual targeting of CRTC1 and PD-L1 demonstrates therapeutic synergy, suggesting CRTC1 pathway inhibition could optimize immunotherapy outcomes in NSCLC patients. This evidence concerns the gene CRTC1 and non-small cell lung carcinoma.